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Intensity modulated proton therapy (IMPT) is a radiation therapy treatment modality that 
offers superior dose conformity in the treatment of a variety of cancers. IMPT may deliver 
simultaneous integrated boost (SIB) to dominant intraprostatic lesions (DILs) detected by 
multiparametric MRI (mpMRI) to improve tumor control in prostate patients. DIL-SIB 
delivered using traditional photon therapy techniques has been demonstrated to achieve 
better clinical outcomes. IMPT can deliver a larger dose to the DIL than photons but is 
more susceptible to dosimetric variation from interfractional anatomic changes. The 
purpose of this thesis is to evaluate the efficacy of IMPT DIL-SIB plans and their 
sensitivity to daily anatomy changes through calculation of tumor control probability 









CHAPTER 1. INTRODUCTION 
1.1   Motivation 
The purpose of radiation therapy in oncology is to control or eradicate cancer cells without 
causing unacceptable damage to normal tissues. Therefore, the goal of any treatment plan 
with a given modality is to maximize the dose delivered to the delineated tumor volume 
while minimizing the dose to organs at risk (OARs). More specifically, a plan must deliver 
a minimum prescribed dose to a certain percentage of the target without exceeding 
maximum dose constraints for normal tissues. The question of which radiation therapy 
modalities and techniques provide the best results for a given tumor type has been the 
subject of extensive research. Proton beam therapy is a unique modality that has been 
applied in the treatment of many different cancers. The characteristic dose distribution of 
protons, in which a significant portion of the energy is deposited at the end of each particle 
track, can be leveraged to decrease dose to normal tissues. Modern treatment delivery 
techniques such as pencil beam scanning may be used to deliver intensity modulated proton 
therapy (IMPT), in which the dose rate is modulated throughout the treatment to ensure 
conformity. Controversy exists over whether the additional cost of proton therapy is 
justified by clearly superior patient outcomes. Long-term clinical studies on the benefits of 
proton therapy are still forthcoming for many cancers, with early evidence often 
conflicting. New treatment techniques that maximize the advantages of proton therapy over 
traditional radiation therapy modalities could justify its use, even at a much higher cost. 
The safety and effectiveness of any new treatment technique may be supported through 
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dosimetric and biological analysis of planning data in the absence of clinical trials 
investigating actual patient outcomes. 
1.2   Proton Therapy for Prostate Cancer 
Prostate carcinoma is the most common cancer occurring in men within the United States, 
accounting for twenty-one percent of new malignances in 2020. It is also responsible for 
ten percent of male cancer deaths, second only to lung and bronchus cancers. Despite its 
commonality, widespread screening and a multitude of treatment techniques have made 
the survival rate high (1). Radiation therapy has been widely used in the treatment of 
prostate cancer for decades. Different modalities and techniques including intensity 
modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), 
stereotactic body radiation therapy (SBRT) and interstitial brachytherapy are prescribed 
depending on the cancer stage and preferences of the patient. The benefits of these 
treatment options in patients of different ages and cancer stages have been the topic of 
many clinical studies and literature. Proton beam therapy has been employed in prostate 
cancer treatment since the early 1990s. Widespread information reporting the theoretical 
benefits of protons has led an increasing number of patients to pursue this type of treatment. 
Prostate patients now account for the majority of proton therapy procedures performed in 
the United States. As previously mentioned, the superior dose conformity that may be 
achieved through the interaction characteristics of protons can decrease the likelihood of 
normal tissue toxicities without sacrificing tumor control. Long-term clinical studies 
demonstrating the benefits of proton therapy for prostate cancer are lacking, as with other 
cancers (2). Initial studies of clinical outcomes have compared proton therapy to other 
modalities using criteria such as tumor control, gastrointestinal and genitourinary 
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toxicities, as well as the risk of secondary malignancies. The results of these studies are 
widely mixed (3).  
1.3   New Treatment Methods 
New techniques for the planning and delivery of proton therapy offer the opportunity to 
increase its efficacy and advantages in the treatment of prostate cancer. Modern IMPT 
delivered using pencil beam scanning is superior to traditional passive scattering when 
considering both range and dose precision (4). IMPT may also be used to accurately deliver 
additional radiation dose to tumor lesions within the prostate, instead of the usual 
homogenous irradiation of the whole volume. This technique may increase the probability 
of tumor control, while also increasing the occurrence of normal tissue damage. A 
significant issue with even modern proton therapy techniques is dosimetric uncertainty, the 
effects of which are made worse by the larger dose deposited over a narrower range. Setup 
errors, range variation, and anatomy changes between fractions can significantly alter the 
planned dose distribution in prostate patients (5) (6). Dose escalation can increase the 
potential for unplanned dose shifts to cause normal tissue damage, as the focal spots 
covering the lesions deliver a very high dose. For novel treatment methods such as IMPT 
prostate lesion boost to be promoted for clinical use, their safety and effectiveness must be 
demonstrated. The analysis of biological endpoints presented in this thesis will provide a 
basis for the use of lesion boost over conventional plans in IMPT, and possibly support the 





CHAPTER 2. BACKGROUND 
2.1   Prostate Patient Simulation 
Simulation methods used in radiation therapy treatment planning for prostate patients 
typically include CT and MRI registrations that are used to identify the prostate, OARs and 
bony anatomy. Other tools such as fiducial markers and dyes may also be implemented to 
localize the target and significant organs. A unique MR imaging technique, known as 
multiparametric MRI (mpMRI) has recently been incorporated into the screening, 
diagnosis, and simulation of prostate cancer. MpMRI typically combines T1, T2 and 
diffusion weighted scans to increase soft tissue contrast and conspicuity. These images may 
be used to detect tumor lesions within the prostate and identify the region of greatest 
disease prominence, known as the dominant intraprostatic lesion (DIL) (7). The ability to 
identify the DIL in prostate patients presents the opportunity for more targeted treatment 
options, the most significant being radiotherapy boost.  
2.2   DIL-SIB 
Once the mpMRI-defined DIL is identified in a prostate patient, a focal boost of radiation 
dose may be delivered to the lesion. The feasibility of DIL focal boost in the treatment of 
prostate cancer has been demonstrated using several different modalities. In patients 
undergoing interstitial brachytherapy, optimized needle patterns may be used to deliver 
additional dose to the DIL for better tumor control (8). A common technique for the 
delivery of focal dose boost using external beam modalities is simultaneous integrated 
boost (SIB), in which varying dose levels are delivered to different target volumes in the 
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same treatment fraction (9). Clinical studies have demonstrated that DIL-SIB is safe and 
effective when delivered with photon IMRT and VMAT. These studies, when comparing 
DIL-SIB with conventional plans, show an improvement in tumor control and disease-free 
patient survival without a significant increase in normal tissue toxicities (10) (11). DIL-
SIB may be administered with IMPT using pencil-beam scanning, in which a number of 
small beamlets are delivered to the target one energy layer at a time. During treatment 
planning, the target volumes are covered with beam spots to deliver a certain dose level to 
the tumor. Evidence supporting the feasibility and possible superiority of DIL-SIB using 
IMPT is much less established, but compelling. Due to the greater dose conformity of 
protons, DIL-SIB delivered with IMPT has been demonstrated to achieve a higher dose to 
the DIL when compared with IMRT or VMAT without violating OAR constraints (12). 
Other planning studies also suggest that IMPT DIL-SIB may improve tumor control while 
meeting all required normal tissue objectives (13).    
2.3   Dosimetric Uncertainty 
A significant problem in modern proton therapy is uncertainty between the planned and 
delivered dose distributions. Any errors or variation in the delivery of a treatment plan may 
have more significant dosimetric consequences than in photon therapy. This is due to the 
characteristic dose distribution of protons, where a larger amount of the dose is deposed 
over a smaller range. In a typical proton therapy treatment plan, the edges of the Bragg 
peak are aligned with the target volume. Since the dose falloff beyond the Bragg peak is 
abrupt, errors during delivery may result in a higher overdose to tissues outside the target 
volume and loss of proper target coverage. One possible source of error is uncertainty in 
the tissue proton ranges calculated during the treatment planning phase. In photon therapy, 
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linear attenuation coefficients of various tissues correlate very closely with Hounsfield 
units calculated from CT simulation. Proton stopping powers, however, cannot be 
estimated with the same accuracy from CT. This leads to a residual uncertainty in the range 
of proton beams and a greater influence of tissue heterogeneity on the dose distribution. 
Therefore, a hallmark of a good proton treatment plan is low susceptibility to possible 
uncertainties in the range, known as robustness. Plans may be optimized based on 
robustness objectives to ensure that the clinical goals are preserved in the presence of range 
variation. A typical standard for acceptable robustness is ±3.5% deviation in the planned 
ranges, as this is the usual uncertainty associated with the proton stopping powers 
calculated from CT scans. A common way that range uncertainties are accounted for in a 
treatment plan is by adding a margin to the delineated clinical target volume (CTV) to 
create the planning target volume (PTV) (14). Additional errors that may alter the delivered 
dose distribution include inaccurate patient setup, as well as changes in patient anatomy 
both during and between treatment fractions. In prostate patients, anatomic changes 
resulting in dosimetric variation can include femur rotation, adipose tissue thickness, and 
rectal and bladder filling (5) (6). Techniques for minimizing this variation include patient 
immobilization deceives, marking and mapping systems for alignment, margins to account 
for motion, and rectal and bladder filling protocols. Some movement is inevitable even 
when using these techniques, although the extent of the dosimetric variation may not be 
predictable. Delivery of focal dose boost to DILs can increase the consequences of any 
variation in positioning or anatomy throughout the treatment. Doses delivered to the DIL 
with SIB may be as high as twice that of the typical uniform dose prescribed to the prostate 
volume. Imprecise delivery of the boost to the DIL can therefore result in significant 
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overdosing of normal tissues in the vicinity of the prostate, rendering the plan unsafe. 
Establishing the safety of IMPT DIL-SIB plans against large dosimetric variation would 
significantly support the practicality of their clinical use.  
2.4   Tumor Control and Normal Tissue Toxicity 
A variety of normal tissue toxicities may occur in the pelvic region as the result of 
overdosing from prostate radiotherapy. Extensive literature exists on different endpoints, 
both early and late, occurring in OARs if certain dose-volume thresholds are exceeded 
during treatment. Major OARs in the pelvic region include the rectum, bladder, bowel, 
urethra, bony anatomy, and sexual organs (15). Rectal toxicities are the most common and 
widely studied complications associated with prostate radiotherapy. The most frequent 
symptom of overdose to the rectum is bleeding, although other early and late effects may 
include necrosis/stenosis, incontinence, and diarrhea (16). Possible injuries to the bladder 
include urinary symptoms, contracture, and necrosis (17). Although less common, effects 
on the pelvic bony anatomy may involve necrosis and increased fracture risk of the femoral 
heads and pelvis (15). Overdose of the urethra may result in perforation and stricture 
followed by corresponding urinary symptoms (18). Bowel overdose may result in similar 
symptoms as rectal toxicity, such as diarrhea and incontinence (15). Sexual dysfunction 
may be caused by overdose of the penile bulb, testicles, and neurovascular bundles (15). 
During treatment planning, normal tissue toxicities may be avoided by ensuring that 
recommended dose-volume thresholds for certain tissues are not exceeded. Tissues with 
serial structure will have a higher threshold dose at a lower volume percentage, as overdose 
to even a small portion can cause serious damage to the function of the organ. Tissues with 
parallel structure typically have a higher threshold volume that may be irradiated to a lower 
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threshold dose (19). Treatment plans may be optimized based on normal tissue objectives 
to ensure that the planning doses do not exceed the recommended thresholds. Optimization 
based on tumor coverage is also necessary so that meeting normal tissue requirements does 
not compromise the dose prescribed to a given percentage of the tumor volume. One way 
of evaluating a treatment plan in terms of tumor control and normal tissue sparing is 
through tumor control probability (TCP) and normal tissue complication probability 
(NTCP). These values may be calculated by combining dose-response and statistical 
models to assess the probability of eradicating all tumor cells in the target volume or 
inducing a given complication in a normal tissue. While more traditional TCP and NTCP 
models are based on dose-volume histograms, modern methods may calculate dose 
response on the voxel level. This allows the model to consider irradiation of different 
tissues from a non-uniform dose distribution (20). Although not accurate representations 
of actual probabilities, TCP and NTCP are extremely useful for comparison of different 
treatment plans and evaluation of the effects of dosimetric changes (21). Calculations of 
these biological metrics for IMPT DIL-SIB plans may establish their benefits in terms of 
tumor control, evaluate the detriment to normal tissues, and assess how dosimetric 






CHAPTER 3. METHODS 
3.1   Patient Data and Simulation 
The data used for this study was obtained from twenty-five prostate patients previously 
treated at Emory Proton Therapy Center in early 2019. RayStation 8B served as the primary 
framework for simulation, planning, and biological evaluation. Prior to their treatment, 
each of the patients were scanned with a CT simulator. MR scans with T1, T2 and diffusion 
weighting were then acquired on the same day using an identical patient setup. The 
obtained MR images were compiled into apparent diffusion coefficient (ADC) maps. The 
resulting mpMR images were then rigidly registered with the CT scans to form the main 
planning images. These images were used to identify and contour the prostate and DIL for 
each patient. The CTV was created based on the contour of the prostate, and an additional 
margin added for the PTV to account for range and setup uncertainties. Significant OARs 
including the bladder, rectum, femoral heads, and urethra were also contoured. A series of 
pre-treatment cone beam CT (CBCT) scans were acquired for each patient over the first 
several days of treatment to assess the anatomy changes between fractions. Most patients 
received four to five scans during the first week of treatment, although several received 
more scans over a longer period. An important assumption made is that the anatomy 
changes occurring during this time frame are mostly representative of the entire treatment 
course, which lasted over a month. Several techniques were implemented during treatment 
and simulation to help reduce setup errors and motion. Fiducial markers were implanted 
into the prostate of each patient to assist with target localization and alignment for each 
treatment fraction. Patients were also secured with vacuum cushions during simulation and 
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treatment and asked to follow protocols of drinking 500 mL of water one hour before 









Figure 1 – Planning image showing contours of the DIL, prostate CTV and OARs 
3.2   Treatment Planning 
Two main treatment plans were created in RayStation for each of the twenty-five patients 
using the planning CT and mpMR registered images. Conventional clinical plans 
delivering the traditional uniform dose to the prostate were designated as “Prostate CTV”. 
These plans were created to deliver a dose of 70 Gy to 98% of the prostate CTV volume in 
28 treatment fractions, using two lateral opposed beams. The DIL-SIB plans were then 
created to achieve the original uniform coverage of the prostate CTV, with an additional 
coverage of 98 Gy to > 95% of the contoured DIL volume. The original beam configuration 
was used for the SIB plans, with the pencil beam spot weighting at different energy levels 
optimized to achieve the objectives. The dose in the SIB plans was prescribed in the same 
number of treatment fractions as in the conventional plans. The completed SIB plans were 
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the prescribed target coverages, in addition to robustness and normal tissue objectives. 
Robust optimization accounted for 5 mm setup uncertainties in all directions and ±3.5% 
uncertainty in proton range. The maximum dose objectives used for normal tissues 
included bladder < 71.5 Gy, rectum < 71 Gy, femoral head < 40 Gy and urethra < 82 Gy. 
An additional dose falloff objective was also added to the DIL in the SIB plans to prevent 
excessive dose to the CTV. To incorporate the dosimetric variation from interfractional 
anatomy changes, separate composite plans were constructed using the series of daily 
CBCT scans. Anatomic changes reflected by the scans were integrated into the patient 
simulation model by deforming the initial planning CT images onto the daily scans, which 
had been registered to the fiducial markers before each treatment. The original contours of 
the CTV, DIL, urethra and femoral heads were copied to these deform registrations, while 
the rectum and bladder were redrawn based on the CBCT. The nominal treatment plans, 
both conventional and SIB, were then applied to the deformed images and the planning 
doses recalculated. To achieve the same effective dose as the nominal plans, the new daily 
planning doses calculated on the deformed planning CTs were summed into single plans. 
Each daily dose was multiplied by a certain factor required to achieve the same number of 
treatment fractions as the original plans. The two composites made for the conventional 






















Figure 4 – Non-uniform dose distribution of DIL-SIB plan 
3.4   Biological Evaluation 
All calculations of TCP and NTCP for the four treatment plans were performed in the 
RayBiology module of RayStation 8B. This program contains different models and tools 
for evaluating the biological response of tissues to the doses from a given treatment plan. 
Individual tissues may be defined in terms of their various radiobiological parameters, then 
mapped to a particular region of interest (ROI) in the patient simulation. The dose response 
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of the ROI may then be modelled in terms of either tumor control or normal tissue 
complications. A series of functions for various targets and normal tissues may be added 
during treatment plan evaluation and used to compare different fractionation schedules or 
dose distributions. All models are voxel-based, first calculating and then summing the 
responses of each voxel in a given ROI. It is assumed that the tissues of tumors and organs 
modeled are relatively homogenous in structure. Most of the data for this study was 
processed with Python scripts in the RayStation scripting interface. This includes mapping 
ROIs with their given tissues, adding biological functions, and calculating the results. 
3.5   TCP Modelling 
TCP was defined in the background section as the probability of eradicating all clonogenic 
cells in a tumor volume. As tumors are generally considered to be parallel in tissue 
organization, even a small number of remaining cells can repopulate the tumor and cause 
relapse. TCP is commonly calculated through a combination of the linear-quadratic cell 
survival model and Poisson statistics. The most basic equation may be expressed in terms 






                            (1) 
Where P(D) is the response probability from a given dose distribution, N0 is the initial 
number of clonogenic tumor cells, d is the fractional dose, n is the number of treatment 
fractions, α and β  are the linear quadratic fractionation parameters, γ is the maximum slope 
of the dose-response curve, and D50 is the dose to achieve a fifty percent response 
probability. The equation assumes that these parameters were derived from clinical trials 
in which a fixed fractionated dose was used (22). As a means of accounting for different 
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fractionation schedules, the total dose nd may be represented as the equivalent dose 




                                                       (2) 
Where all parameters are the same as in equation (1). A more general formula for 
calculating the EQD2 from unequal fractional doses delivered to different partial volume 








                                                  (3) 
Where EQD2,i is the EQD2 of a volume element or voxel, i is the voxel number, k is the 
fraction number, and dk,i is the dose to voxel i from fraction k. By combining equations (1) 
and (3), the Poisson-LQ TCP model used in the RayBiology module may be expressed in 
both the theoretical and clinical forms as follows (23). 
𝑇𝑇𝑇𝑇𝑃𝑃(𝐷𝐷) = ∏ �𝑒𝑒𝑒𝑒𝑒𝑒 �−𝑁𝑁0𝑒𝑒𝑒𝑒𝑒𝑒�∑ �−𝛼𝛼𝑑𝑑𝑘𝑘,𝑖𝑖 − 𝛽𝛽𝑑𝑑𝑘𝑘.𝑖𝑖2 �𝑛𝑛𝑘𝑘=1 ���
𝑣𝑣𝑖𝑖
𝑣𝑣𝑟𝑟𝑒𝑒𝑟𝑟𝑀𝑀
𝑖𝑖=1   
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𝑖𝑖=1                   (4) 
Where vi is the volume of a voxel, vref is the total reference volume, M is the total number 
of voxels, and Nv is the total number of EQD2 from all voxels. These equations account 
for non-uniform dose distributions by calculating the response of a partial volume, and then 
summing the responses from all partial volumes in the ROI. This model was used in the 
study to calculate the TCP for two target volumes in each plan, the contoured DIL and the 
prostate CTV minus the DIL. The choice was made to calculate TCP for these volumes 
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separately due to differing model parameters between the prostate and lesion tissues (24) 
(25). Similar methodology has also been used in other studies where TCP was calculated 
for prostate lesions (8). The parameters for the Poisson-LQ model used in this study are 
summarized in Table 1. The values of D50 and γ for the prostate and DIL were obtained 
from a study in which clinical patient follow-up data was fitted to the Poisson-LQ model 
(25). Since the α/β parameter for prostate cancer has still not been estimated precisely (26), 
the TCP calculations were performed twice using the two common values of 1.5 and 3.0. 
These represent reasonable higher and lower estimates of the actual value and have been 
used in similar studies (8). The TCP values for multiple tumors treated by the same plan 
may be combined through simple multiplication into a single value. The composite TCP, 
which expresses the total probability of controlling all tumor sites, can be calculated by the 
following equation (23).     
𝑇𝑇𝑇𝑇𝑃𝑃(𝐷𝐷) = ∏ 𝑇𝑇𝑇𝑇𝑃𝑃𝑗𝑗(𝐷𝐷)𝑗𝑗                                               (5) 
Where TCPj(D) is the TCP from dose D of target volume j. 
Table 1 – Parameters used for the Poisson-LQ TCP model 
Target α/β (Gy) D50 (Gy) γ  Reference 
DIL 1.5 / 3.0 68.1 4.5 (25) 






3.6   NTCP Modelling  
The RayBiology module contains two different models for estimating NTCP. The first is 
based on a similar combination of the linear-quadric response model and Poisson statistics 
as the TCP model. The primary difference is that the normal tissues considered by any 
NTCP model are partially serial in nature, instead of entirely parallel as with tumors. This 
structural difference leads to a unique volume dependence in normal tissues, which may 
be accounted for by an additional parameter. The relative seriality NTCP model 
incorporates the parameter s, which represents the fraction of total functional subunits in 
the tissue volume that are serial in nature (27). A small value of the s parameter therefore 
implies a minimal sensitivity to dose hot spots.  Based on the relative seriality model, the 
RayStation equation for the Poisson-LQ NTCP model may be expressed as follows (23). 
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   (6) 
Where s is as defined above, and all other parameters are the same as in equation (4). The 
second NTCP model included in the RayBiology module is based on significantly different 
principles than either Poisson-LQ model. The Lyman-Kutcher-Burman (LKB) NTCP 
model uses an integral to calculate the total response probability of a number of partial 
volumes using estimations from known responses. The RayStation formulation of the 
model includes the three following separate equations (23).  
𝑁𝑁𝑇𝑇𝑇𝑇𝑃𝑃𝐿𝐿𝐿𝐿𝐿𝐿(𝐷𝐷) =
1
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𝑖𝑖=1                                            (9) 
Where t is the standard deviation of the dose-volume distribution, Deff is the equivalent 
uniform dose, m is the slope of the response curve, and n is the volume dependence of the 
tissue. The first equation expresses the NTCP as an integral based on a probit function, the 
second calculates the standard deviation, and the third converts the partial volume doses 
into the equivalent uniform dose (23) (28). The relative seriality model was favored for this 
study, as it has a more robust biological base and accounts for the seriality of tissues. The 
LKB model, however, has a much longer history of clinical use and more extensive 
literature estimating its parameters. Based on the availability of reliable model parameters 
for desired organs and endpoints, the relative seriality model was used to calculate NTCP 
for the bladder and femoral heads, while the LKB model was used for the urethra and 
rectum. These OARs and their given endpoints were chosen to represent common normal 
tissue toxicities prevalent in prostate patients, and for their use in other similar studies (29). 
The parameters used with a given model for each OAR and its corresponding endpoints 
are summarized in Table 2. NTCP values calculated for different OARs in the same 
treatment plan may also be combined into a single composite value. The composite NTCP 
considering j OARs may be calculated using the following formula (23).  
𝑁𝑁𝑇𝑇𝑇𝑇𝑃𝑃(𝐷𝐷) = 1 −∏ (1 − 𝑁𝑁𝑇𝑇𝑇𝑇𝑃𝑃𝑗𝑗(𝐷𝐷))𝑗𝑗                                   (10) 
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Where NTCPj(D) is the NTCP from dose D of normal tissue j. The composite TCP and 
NTCP values for a given plan can be used to calculate the following single metric to assess 
the overall quality of the plan (23).  
𝑃𝑃+ = 𝑇𝑇𝑇𝑇𝑃𝑃(𝐷𝐷)(1− 𝑁𝑁𝑇𝑇𝑇𝑇𝑃𝑃(𝐷𝐷))                                      (11) 
Where P+ is the probability of complication-free tumor control, TCP(D) is the composite 
TCP and NTCP(D) is the composite NTCP. If composite NTCP and P+ values were being 
used as an objective measurement of individual plan quality, the OARs considered would 
have to be carefully chosen. Minor complication endpoints that have the same NTCP as 
serious toxicities could not be given the same weight for obvious reasons. Since these 
metrics are only being used to compare plans in this study, all OARs for which NTCP was 
calculated will be considered.  
Table 2 – Parameters used for the relative seriality and LKB NTCP models 




γ s n m Reference 
Rectum ≥ Grade 2 
Bleeding 
3.0 76.9 - - 0.09 0.13 (16) 
Femoral 
Heads 
Necrosis 3.0 65.0 2.7 1.0 - - (30) 
Bladder Contracture 3.0 80.0 3.0 0.18 - - (30) 





CHAPTER 4. RESULTS 
4.1   Dosimetric and Anatomic Variation 
Several measurements were made before the biological evaluation to assess the daily 
variations in patient anatomy and the resulting changes in the dosimetry of the plans. 
Average anatomic changes shown by the daily CBCT scans include a 0.6% increase in 
bladder volume, a 12.8% increase in rectal volume, and a 3.16 mm shift in femur position. 
Average dosimetric variations in the SIB plans include a 1.1% decrease in the CTV D99, 
a 3.1% decrease in the DIL V98, a 3.6% increase in the max bladder dose, and a 6.8% 
increase in the max rectum dose. These measurements give some context to the TCP and 
NTCP results and how they are affected by the dosimetric variation (31). 
4.2   TCP Data 
With the TCP computed for both the CTV and DIL using the two different α/β ratios, a 
total of four TCP values were collected for each plan. Sixteen were therefore recorded for 
each patient from the four created plans. The composite TCP was calculated by multiplying 
the individual TCPs of the CTV and DIL, for both α/β ratios. The mean values of each TCP 
obtained from all twenty-five patients are summarized in Table 3. The plots (a) and (b) in 






Table 3 – Mean TCP values for each plan 
Plan TCP DIL 
(α/β = 1.5) 
TCP CTV 
(α/β = 1.5) 
TCP DIL 
(α/β = 3) 
TCP CTV 
(α/β = 3) 
Comp. 
TCP  
(α/β = 1.5) 
Comp. 
TCP  
























































4.3   NTCP Data 
As described in the methodology, the NTCP was evaluated in each plan for the urethra, 
rectum, bladder, and left and right femoral heads. The calculations from all four plans 
therefore include twenty NTCP values for each patient. The composite NTCP was 
calculated for each individual plan considering the NTCP for all OARs. The P+ values 
were also calculated using the composite NTCP and the composite TCP with both α/β 
ratios. The mean NTCP values for each OAR and the composite NTCPs are shown in Table 
4. The mean P+ calculations for the two α/β rations are shown Table 5. The distribution of 
the composite NTCP data is shown by plot (c) in Figure 5.   
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Table 5 – Mean P+ values for each plan using TCP from both α/β ratios 
Plan P+ (α/β = 1.5) P+ (α/β = 3.0) 
Prostate CTV 0.80807±0.00625  0.74486±0.00593  
SIB CTV 0.84955±0.00739  0.82266±0.00725 
Prostate CTV Sum 0.80779±0.00534  0.74325±0.00506  























(c) Composite NTCP 
Figure 5 – Distribution of composite TCP and NTCP data from all patients 
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4.4   Hypothesis Testing 
The uncertainties assigned to each of the mean values listed in Tables 3-5 were calculated 
as the standard error of the sample mean, using the sample standard deviation. A series of 
hypothesis tests were performed with the mean values and standard deviations using a two-
tailed pooled t-test for two normal means with variances approximately equal. The null 
hypothesis of these tests assumes no difference in the sample means being compared, with 
the alternative hypothesis being a significant difference. These tests were performed for 
the comparison of the mean composite TCPs and NTCPs between the conventional and 
SIB plans, and additionally between the nominal and composite forms of both plans. The 
p-values calculated from the hypothesis tests are listed in Tables 6, 7 and 8.  
 
Table 6 – P-values for comparison of mean composite NTCP values  
Test P-value 
Prostate CTV vs. SIB CTV 0.343 
Prostate CTV Sum vs. SIB CTV Sum 0.128 
SIB CTV vs. SIB CTV Sum 0.736 







Table 7 – P-values for comparison of mean composite TCP with α/β = 1.5 
Test P-value  
Prostate CTV vs. SIB CTV < 0.001 
Prostate CTV Sum vs. SIB CTV Sum < 0.001 
SIB CTV vs. SIB CTV Sum 0.821 
Prostate CTV vs. Prostate CTV Sum 0.305 
 
Table 8 – P-values for comparison of mean composite TCP with α/β = 3.0 
Test P-value  
Prostate CTV vs. SIB CTV < 0.001 
Prostate CTV Sum vs. SIB CTV Sum < 0.001 
SIB CTV vs. SIB CTV Sum 0.829 
Prostate CTV vs. Prostate CTV Sum 0.270 







CHAPTER 5. DISCUSSION 
5.1   Summary of Results  
The results of the TCP and NTCP calculations may be analyzed in several different ways 
to assess the clinical superiority of DIL-SIB plans using IMPT. First, the direct benefits of 
the SIB plans may be evaluated by comparing their TCP and NTCP values with the 
conventional plans, considering both the nominal and composite forms. It may be observed 
that the SIB plans have much higher mean composite TCP values than the conventional 
plans, both nominal and composite. The small p-values of the tests comparing TCP for 
Prostate CTV vs. SIB CTV and Prostate CTV Sum vs. SIB CTV Sum show that these 
differences are highly significant. This observation is true when considering the mean 
composite TCP for both values of α/β. Closer examination of the individual TCP values 
show a large increase for the DIL in the SIB plans, with a smaller increase for the CTV. 
This is the expected result, as the focal boost to the DIL volume will increase its TCP while 
also delivering additional residual dose to the CTV. Comparison of the mean composite 
NTCP shows a small increase in the nominal and composite SIB plans from the 
conventional. This same observation may be made of the individual NTCP values for each 
OAR. A marginal increase in the probability of normal tissue toxicities is also expected in 
the SIB plans due to the higher doses associated with the focal spot. This increase is not 
significant based on the tests comparing the NTCP of Prostate CTV vs. SIB CTV and 
Prostate CTV Sum vs. SIB CTV Sum. These initial observations are promising, as they 
support the ability of the SIB plans to achieve better tumor control with minimal increase 
in the occurrence of normal tissue toxicities. The higher P+ values of the SIB plans with 
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either α/β ratio also convey these findings. The second and more pertinent question that 
may be addressed from the data is whether the dosimetric variation in the composite SIB 
plans leads to a significant degradation of tumor control or an increase in the likelihood of 
normal tissue damage. This question may be assessed through comparison of the results in 
a different way, with the nominal SIB and conventional plans contrasted against their 
composite forms. The mean composite TCP value for the composite conventional plan 
shows a small decrease from the nominal plan. This is yet another expected result, as the 
dose variation reflected in the composite plan can lead to a lack of target coverage. 
Surprisingly, a small increase may be seen in the mean composite TCP of the SIB plans 
due to the variation. This could be the product of a higher dose delivered to the CTV 
through variation in the focal spot position, while still maintaining sufficient DIL coverage. 
These observations are also consistent for both α/β ratios and the individual TCPs of the 
DIL and CTV. The p-values for SIB CTV vs. SIB CTV Sum and Prostate CTV vs. Prostate 
CTV Sum show that neither the decrease in mean composite TCP for the conventional 
plans or the increase for the SIB plans is significant. Lastly, examination of mean 
composite NTCP reveals a small increase in the SIB plans from the dosimetric variation. 
This is expected due to the likelihood of a higher dose to normal tissues from focal spot 
deviation. The same slight increase is seen in the mean NTCP values for each OAR. When 
comparing the NTCP values for the nominal and composite conventional plans, an 
unexpected decrease in NTCP may be seen. The explanation for a lower NTCP when 
considering dosimetric variation is not immediately clear. The difference could be the 
result of a methodological error such as the choice of OARs. Examination of the p-values 
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for comparison of SIB CTV vs. SIB CTV Sum and Prostate CTV vs. Prostate CTV Sum 
again reveal minimal significance of the observed differences in NTCP.  
5.2   Limitations 
Despite the compelling observations made from the results, possible shortcomings of the 
methodology must be noted to contextualize any conclusions. One limitation lies in the 
inherent uncertainties associated with the biological modelling. While TCP and NTCP are 
useful metrics for the comparison or optimization of plans with different dose distributions 
and fractionation schedules, they are not always accurate predictors of clinical outcomes. 
The choices of models, parameters, OARs, and endpoints all affect the results of TCP and 
NTCP calculations. Different models using parameters obtained with varying methods and 
patient populations will seldom yield identical results. The practical limitation on the 
number of OARs and endpoints that are considered for NTCP calculations can also alter 
the outcome. It is possible that dosimetric variation in the SIB plans may lead to toxicities 
in normal tissues that were not considered, or different endpoints in the tissues that were. 
Another limitation of the methodology is in the assumption that any dosimetric variation 
from patient anatomy changes occurring during the first week are representative of the 
entire treatment course. Since most of the patients only received the several daily CBCT 
scans during the first treatment week, this was the only data representing any anatomic 
changes that was available for this study. It is possible that more significant changes could 
occur over a longer period of the treatment, leading to larger dose shifts and further normal 
tissue damage or loss of target coverage. A compelling argument supporting the viability 
of the methodology may be made by considering the TCP and NTCP calculations for 
individual patients. As mentioned in the methods section, several of the patients received 
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additional CBCT scans over longer periods of time. It may be observed that the TCP and 
NTCP values for these specific patients are not significantly different from the averages. 
These individual values are also consistent with the conclusions of the various hypothesis 
tests. Therefore, it is probable that no significant variations in TCP or NTCP would occur 
if the anatomy changes from a longer period of the treatment were represented in the 
analysis. A final limitation in the methodology that should be discussed is the possible 
influence of range uncertainties on the results. As outlined in the background section, the 
inaccurate calculation of proton stopping powers from CT scans can lead to additional 
variation in the delivered dose distribution. The effects of possible uncertainties in proton 
ranges may be simulated in most treatment planning systems but were not incorporated 
into the plans considered by this study. The plans were, however, optimized based on the 
robustness objectives specified in the methods section. This optimization and the additional 
margin added to the target should significantly reduce the susceptibility of the plans to any 
range variations. Other studies have also shown that setup and range uncertainties only 
have a small effect on TCP and NTCP in IMPT plans, even without robust optimization 
(32). Although it may be unlikely that range variations would have significantly altered the 
TCP and NTCP calculations for the conventional plans, it is possible that the focal boost 
in the SIB plans could worsen the effects. Further investigation into the effects of range 
uncertainties on TCP and NTCP in IMPT DIL-SIB would therefore be useful. A potential 
solution to the problem of both range and anatomic variations is adaptive radiotherapy, in 
which treatment plans are optimized between fractions to account for any dosimetric 
changes. This continuous updating of plans can reduce the extra margins required to 




Two main conclusions may be drawn from the analysis that support the clinical superiority 
of DIL-SIB in IMPT. One is that DIL-SIB almost certainly increases the tumor control of 
both the DIL and CTV, with no major changes in the standard possibilities for normal 
tissue toxicities. The second conclusion is that DIL-SIB plans are not any more susceptible 
to the biological effects of interfractional dosimetric variation than conventional plans. 
These conclusions therefore suggest that DIL-SIB is a reasonably safe and effective way 
to achieve better prostate tumor control with IMPT than uniform irradiation plans. The 
results of this study are a promising piece of theoretical evidence supporting the clinical 
use of DIL-SIB in IMPT. To confirm the actual benefits and safety of these plans as 
suggested by the TCP and NTCP calculations, studies of clinical outcomes must be 
performed. These studies would have a similar structure as those that have supported 
photon DIL-SIB, investigating endpoints such as disease-free patient survival and 
complications. Further demonstration that DIL-SIB using IMPT offers improved outcomes 
when compared with traditional IMPT or other modalities would support the overall use of 
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